Tissue Acquisition And Cellular/Molecular Analysis Shared Resource (TACMASR)

组织获取与细胞/分子分析：摘要 癌症的个性化治疗正迅速成为一种标准做法。有几个因素导致了 患者的独特性，包括个体的基因组、癌症、疾病的基因组和表观基因组 呈现、性别、暴露、生活方式、微生物群和其他共生体。特定身份的识别 肿瘤内的生物标志物、信号通路、免疫细胞特征和基因突变是其基础 分子靶向治疗和癌症治疗的新见解。项目需要人类的组织样本 肿瘤，可植入小鼠模型或用于产生器官型培养物， 复制人类疾病的进展和对治疗的反应。新药治疗将首先在 这些临床前模型在开发的治疗方法进入临床试验之前使用了患者样本。 此外，破译遗传改变以及变异和肿瘤相关基因也被用作 该患者独有的靶向治疗。组织获取的总体目标&细胞/分子 分析共享资源(TACMASR)旨在促进个性化方法的早期发现和 利用生物标记物/药物发现的新的研究病理学维度进行癌症治疗，数字和 空间成像，以及3D培养的创新形态分析。通过继续强调 推进临床和转化性研究，增加基础和临床之间的合作 调查人员，TACMASR作为一个集中资源，为亚利桑那大学癌症中心提供 (UACC)有权获得经过临床注释的高质量人体标本的成员。TACMASR提供 综合生物信息库与先进的人和动物组织分析相结合，使用最先进的 显微镜、3D器官培养，以及训练有素的工作人员对结果的专家分析和解释。这个 TACMASR的具体目标是：(1)为收集提供无缝过程的生物标本， 人体组织的加工、储存和分配；(2)支持提供全方位服务的研究组织学实验室 提供常规和专门的石蜡包埋、切片、自动苏木精和伊红染色， 冰冻切片和大量特殊染色的选择；以及(3)开发新的方案和最先进的技术 技术，以满足提出请求的调查人员的特殊需要，并培养针对调查人员的个性化方法 癌症的早期发现和治疗。在2020财年，TACMASR为81个独立用户(53%的UAcc)提供服务 成员)。自2016年以来，这些服务为UACC成员的47份出版物和29份赠款提供了捐助。

TISSUE ACQUISITION & CELLULAR/MOLECULAR ANALYSIS: ABSTRACT Personalized treatment of cancer is rapidly becoming a standard practice. Several factors contribute to the uniqueness of a patient, including the individual’s genome, the genome and epigenome of the cancer, disease presentation, gender, exposures, lifestyle, microbiome, and other comorbidities. The identification of specific biomarkers, signaling pathways, immune cell signatures and genetic mutations within tumors underlies molecular targeted therapies and new insights into cancer treatment. Projects require tissue samples of human tumors, which may be implanted in mouse models or used for the generation of organotypic cultures that duplicate the human disease progression and response to treatment. New drug treatments will first be tested in these preclinical models using patient samples before developed therapeutic approaches reach clinical trials. In addition, deciphering genetic alterations and aberrant and tumor-related genes are used for biomarkers for targeted therapies that is unique to that patient. The overall goal of the Tissue Acquisition & Cellular/Molecular Analysis Shared Resource (TACMASR) is to foster individualized approaches for the early detection and therapy of cancers utilizing a new dimension of research pathology for biomarker/drug discovery, digital and spatial imaging, and innovative morphological analysis of 3D cultures. Through continued emphasis on advancing clinical and translational research and increasing collaborations among basic and clinical investigators, TACMASR serves as a centralized resource, providing University of Arizona Cancer Center (UACC) Members with access to clinically annotated, high-quality human specimens. TACMASR offers a comprehensive biorepository coupled with advanced human and animal tissue analysis using state-of-the art microscopy, 3D organotypic cultures, and expert analysis and interpretation of results by well trained staff. The Specific Aims of TACMASR are to: (1) provide biospecimens with a seamless process for the collection, processing, banking, and distribution of human tissues; (2) support a full service research histology laboratory that offers routine and specialized paraffin embedding, sectioning, automated hematoxylin and eosin staining, frozen sectioning, and a large selection of special stains; and (3) develop new protocols and state-of-the-art technologies to meet the special needs of requesting investigators and foster individualized approaches for the early detection and therapy of cancers. In CY20, TACMASR provided services to 81 unique users (53% UACC Members). Services since 2016 have contributed to 47 publications by UACC Members and 29 grants.